Valeant's Revenue Falls 13%

Valeant Pharmaceuticals said its revenue fell 13% in the fourth quarter, hurt by the performance of the stomach-drug business it tried to sell late last year as well as lower drug prices.

Source: WSJ.com: Health - March 1, 2017 Category: Pharmaceuticals Tags: PAID Source Type: news